Open Access68Gallium-prostate-specific membrane antigen ligand positron-emission tomography or computed tomography in biochemical failure after radical prostatectomy: A case report
Author(s) -
Irene A. Chidothe,
David Anderson
Publication year - 2017
Publication title -
south african journal of oncology/south african journal of oncology
Language(s) - English
Resource type - Journals
eISSN - 2523-0646
pISSN - 2518-8704
DOI - 10.4102/sajo.v1i0.16
Subject(s) - prostatectomy , prostate cancer , positron emission tomography , glutamate carboxypeptidase ii , medicine , magnetic resonance imaging , management of prostate cancer , biochemical recurrence , nuclear medicine , prostate , radiology , positron emission tomography computed tomography , prostate specific antigen , cancer
Biochemical failure after radical treatment for prostate cancer occurs in up to 30% – 50% of cases. Localisation of clinical disease is challenging because clinical symptoms often manifest long after the initial rise in prostate-specific antigen. The detection rates of imaging modalities such as contrasted computed tomography (CT), bone scan, magnetic resonance imaging and choline positron-emission tomography (PET) or CT, are limited. Prostate-specific membrane antigen (PSMA) ligand PET or CT is a novel imaging modality under investigation for various diagnostic and therapeutic indications in the management of prostate cancer. We present a case report illustrating how 68 Gallium-PSMA ligand PET or CT was used to guide management in a patient presenting with biochemical failure after radical prostatectomy.